Kakeru Hisakane

547 total citations
35 papers, 336 citations indexed

About

Kakeru Hisakane is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Kakeru Hisakane has authored 35 papers receiving a total of 336 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 23 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Kakeru Hisakane's work include Lung Cancer Treatments and Mutations (16 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (10 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Kakeru Hisakane is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (10 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Kakeru Hisakane collaborates with scholars based in Japan, United States and China. Kakeru Hisakane's co-authors include Akihiko Gemma, Masahiro Seike, Rintaro Noro, Teppei Sugano, Satoshi Takahashi, Kaoru Kubota, Susumu Takeuchi, Yuji Minegishi, Takeru Kashiwada and Kuniko Matsuda and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Gene.

In The Last Decade

Kakeru Hisakane

30 papers receiving 334 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kakeru Hisakane Japan 10 215 179 77 67 27 35 336
Ina Valeria Zurlo Italy 6 89 0.4× 105 0.6× 36 0.5× 40 0.6× 42 1.6× 24 191
Go Makimoto Japan 10 193 0.9× 147 0.8× 81 1.1× 23 0.3× 34 1.3× 60 298
Norimitsu Kasahara Japan 10 163 0.8× 196 1.1× 40 0.5× 38 0.6× 22 0.8× 29 301
Guannan Kang China 6 164 0.8× 80 0.4× 70 0.9× 183 2.7× 21 0.8× 11 275
Emma Spurrell United Kingdom 7 184 0.9× 144 0.8× 63 0.8× 40 0.6× 20 0.7× 11 307
Chang Hun Lee South Korea 11 230 1.1× 128 0.7× 88 1.1× 73 1.1× 68 2.5× 23 375
N. А. Oskina Russia 6 249 1.2× 201 1.1× 89 1.2× 31 0.5× 34 1.3× 15 339
László Agócs Hungary 5 96 0.4× 220 1.2× 104 1.4× 37 0.6× 63 2.3× 20 290
Haolin Yan China 10 118 0.5× 97 0.5× 66 0.9× 63 0.9× 109 4.0× 21 302
Yun‐Zhi Lin China 13 209 1.0× 61 0.3× 130 1.7× 103 1.5× 77 2.9× 32 378

Countries citing papers authored by Kakeru Hisakane

Since Specialization
Citations

This map shows the geographic impact of Kakeru Hisakane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kakeru Hisakane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kakeru Hisakane more than expected).

Fields of papers citing papers by Kakeru Hisakane

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kakeru Hisakane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kakeru Hisakane. The network helps show where Kakeru Hisakane may publish in the future.

Co-authorship network of co-authors of Kakeru Hisakane

This figure shows the co-authorship network connecting the top 25 collaborators of Kakeru Hisakane. A scholar is included among the top collaborators of Kakeru Hisakane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kakeru Hisakane. Kakeru Hisakane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Iida, Hiroki, S Takashima, Ayana Suzuki, et al.. (2025). Allergic bronchopulmonary mycosis induced by pembrolizumab for bladder cancer: A case report. Respiratory Medicine Case Reports. 54. 102179–102179.
2.
Hisakane, Kakeru, et al.. (2024). Evaluation of sarcoidosis with multiple bone lesions using both bone scintigraphy and FDG-PET/CT: A case report. Respiratory Medicine Case Reports. 51. 102077–102077. 1 indexed citations
3.
Tozuka, Takehiro, Rintaro Noro, Hideaki Mizutani, et al.. (2024). Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer. Lung Cancer. 191. 107540–107540. 9 indexed citations
4.
5.
Kamio, Koichiro, Akihiko Miyanaga, Keisuke Yoshida, et al.. (2024). Ivermectin Enhances Paclitaxel Efficacy by Overcoming Resistance Through Modulation ofABCB1in Non-small Cell Lung Cancer. Anticancer Research. 44(12). 5271–5282.
6.
Hisakane, Kakeru, et al.. (2024). Safety and Efficacy of Gefitinib Administration After Osimertinib-Induced Interstitial Lung Disease: A Six-Case Series. OncoTargets and Therapy. Volume 17. 717–726. 1 indexed citations
7.
Liu, Weiran, Chen Chen, Qiang Zhang, et al.. (2024). Histopathologic pattern and molecular risk stratification are associated with prognosis in patients with stage IB lung adenocarcinoma. Translational Lung Cancer Research. 13(9). 2424–2434.
8.
Hisakane, Kakeru, et al.. (2023). A remarkable response to combination chemotherapy with nivolumab and ipilimumab in a patient with primary pulmonary choriocarcinoma: a case report. Translational Cancer Research. 12(8). 2212–2218. 2 indexed citations
9.
10.
Hisakane, Kakeru, et al.. (2023). Minimal effective dose of maintenance steroid therapy for relapse of cryptogenic organizing pneumonia. Respiratory Medicine. 218. 107390–107390. 1 indexed citations
11.
12.
Seike, Masahiro, Teppei Sugano, Kuniko Matsuda, et al.. (2022). A Novel Molecular Target in EGFR-mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed. Anticancer Research. 42(2). 709–722. 5 indexed citations
13.
Hisakane, Kakeru, Masahiro Seike, Teppei Sugano, et al.. (2021). PD-L1 Expression Status Predicting Survival in Pulmonary Pleomorphic Carcinoma. Anticancer Research. 41(5). 2501–2509.
14.
Minegishi, Yuji, Kakeru Hisakane, Satoshi Takahashi, et al.. (2019). Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study. International Journal of Clinical Oncology. 24(12). 1543–1548. 22 indexed citations
15.
Ariyasu, Ryo, Junji Koyama, Tomoyo Oguri, et al.. (2019). Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995–2017. Lung Cancer. 131. 69–77. 31 indexed citations
16.
Tozuka, Takehiro, Masahiro Seike, Yuji Minegishi, et al.. (2018). Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression. OncoTargets and Therapy. Volume 11. 5601–5605. 5 indexed citations
17.
Hisakane, Kakeru, Kiyotaka Yoh, Naoki Nakamura, et al.. (2017). Salvage chemoradiotherapy with cisplatin and vinorelbine for postoperative locoregional recurrence of non-small cell lung cancer. Medicine. 96(47). e8635–e8635. 10 indexed citations
18.
Naito, Masahito, Keiju Aokage, Kakeru Hisakane, et al.. (2016). Microenvironmental changes in the progression from adenocarcinoma in situ to minimally invasive adenocarcinoma and invasive lepidic predominant adenocarcinoma of the lung. Lung Cancer. 100. 53–62. 17 indexed citations
19.
Goto, Masaki, Masahito Naito, Koichi Saruwatari, et al.. (2016). The ratio of cancer cells to stroma after induction therapy in the treatment of non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology. 143(2). 215–223. 5 indexed citations
20.
Hisakane, Kakeru, Koichi Saruwatari, Satoshi Fujii, et al.. (2015). Unique intravascular tumor microenvironment predicting recurrence of lung squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology. 142(3). 593–600. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ina Valeria Zurlo Breakdown of academic impact, for papers by Go Makimoto Breakdown of academic impact, for papers by Norimitsu Kasahara Breakdown of academic impact, for papers by Guannan Kang Breakdown of academic impact, for papers by Emma Spurrell Breakdown of academic impact, for papers by Chang Hun Lee Breakdown of academic impact, for papers by N. А. Oskina Breakdown of academic impact, for papers by László Agócs Breakdown of academic impact, for papers by Haolin Yan Breakdown of academic impact, for papers by Yun‐Zhi Lin
Rankless by CCL
2026